Michael Newman

Company: Indaptus Therapeutics, Inc.

Job title: Founder and Chief Scientific Officer

Seminars:

Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity 11:30 am

Taking advantage of a rapidly cleared, multi-immune receptor agonist package to induce safe, systemic innate and adaptive immune activation in pre-clinical models (Pulse-Prime hypothesis) Confirmation of the Pulse-Prime hypothesis in an advanced solid tumor clinical trialRead more

day: Day 1 - Track B - AM